Study to investigate the effect of a single dose of AZD7624 on inflammation caused by an endotoxin challenge

Study identifier:D2550C00004

ClinicalTrials.gov identifier:NCT01937338

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A Double blind, Randomised, Placebo-controlled, 2-period, Cross-over Study in Healthy Volunteers to Investigate the Effects of a Single Dose of Inhaled AZD7624 on White Blood Cells and Inflammatory Markers in Induced Sputum and Blood after Oral Inhalation of 45,000 Endotoxin Units Lipopolysaccharide (LPS)

Medical condition

LPS Challenge, Neutrophils

Phase

Phase 1

Healthy volunteers

Yes

Study drug

AZD7624, Placebo

Sex

All

Actual Enrollment

60

Study type

Interventional

Age

18 Years - 55 Years

Date

Study Start Date: 01 Oct 2013
Primary Completion Date: 01 Apr 2014
Study Completion Date: 01 Apr 2014

Study design

Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Crossover Assignment
Masking: Double Blind
Primary Purpose: Basic Science

Verification:

Verified 01 Nov 2016 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria